You are viewing the site in preview mode
Skip to main content
|
Patient characteristics
|
N (%)
|
|---|
|
Age
|
|
Median age, years (range)
|
52.5 (18–78)
|
|
< 65
|
87 (85.3)
|
|
≥ 65
|
15 (14.7)
|
|
Gender
|
|
Male
|
70 (68.6)
|
|
Female
|
32 (31.4)
|
|
ECOG PS
|
|
0
|
19 (18.6)
|
|
1
|
83 (81.4)
|
|
Prior lines of systemic therapy
|
|
1
|
42 (41.2)
|
|
2
|
34 (33.3)
|
|
3 or above
|
26 (25.5)
|
|
Stage of disease#
|
|
I–II
|
17 (16.7)
|
|
III–IV
|
84 (82.4)
|
|
Pathological subtype$
|
|
PTCL-NOS
|
41 (40.2)
|
|
ENKTL
|
23 (22.5)
|
|
ALCL ALK-
|
12 (11.8)
|
|
ALCL ALK+
|
7 (6.9)
|
|
Other subtypes*
|
19(18.6)
|
|
Prior therapies
|
|
Multi-agent regimen
|
|
For ENKTL
|
|
Asparaginase-based chemotherapy†
|
21 (91.3)
|
|
For other subtypes of PTCL
|
|
Anthracycline-containing chemotherapy‡
|
77 (97.5)
|
|
Single-agent regimen
|
|
Chidamide
|
24 (23.5)
|
|
Gemcitabine
|
55 (53.9)
|
|
Methotrexate
|
10 (9.8)
|
|
Bortezomib
|
1 (1.0)
|
|
Radiotherapy
|
32 (31.4)
|
|
Autologous stem-cell transplantation
|
7 (6.9)
|
- ENKTL, extranodal natural killer/T cell lymphoma, nasal type; ALCL, anaplastic large-cell lymphoma; ALK, anaplastic lymphoma kinase; CHOP, cyclophosphamide, doxorubicin, vincristine, prednisone; ECOG, Eastern Cooperative Oncology Group; PS, performance status; NOS, not otherwise specified; PTCL, peripheral T cell lymphoma
- #Stage information of one case was not available
- $PTCL was pathologically diagnosed by study site pathologist for study enrolment
- *Other subtypes included: 11 cases of unclassifiable PTCL, 3 cases of type II enteropathy-associated T cell lymphoma (EATL, type II), 3 cases of mycosis fungoides (MF), 1 case of skin γ σ cutaneous T cell lymphomas (γ σ CTCL), and 1 case of primary cutaneous CD4 positive T cell lymphoma (CD4 + PCTCL)
- †The proportion (%) was defined as the number of patients receiving asparaginase-based chemotherapy divided by the number of those diagnosed with ENKTL
- ‡The proportion (%) was defined as the number of patients receiving anthracycline-containing chemotherapy divided by the number of those diagnosed with other subtypes of PTCL except for ENKTL
